
    
      This is a multicentre, open labeled, prospective, randomized, controlled phase I/II study
      designed to assess the clinical performance of chemoembolization with LC Bead, loaded with
      irinotecan in combination with intravenous chemotherapy and bevacizumab versus intravenous
      chemotherapy in combination with bevacizumab in the treatment of unresectable liver
      metastases in patients with colorectal cancer.
    
  